Disclosures for "Risk Stratification of Hypertension Induced by CGRP Antagonist in Migraine Treatment: A Retrospective Observational Analysis"
-
Dr. Kumar has nothing to disclose.
-
Mr. Subramanian has nothing to disclose.
-
Miss Salimath has received personal compensation for serving as an employee of Quartino Chicago.
-
Mr. Abraham has nothing to disclose.
-
Mr. Sankar has nothing to disclose.
-
Dr. Patel has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eidos. Dr. Patel has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Astra Zeneca. Dr. Patel has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi-Genzyme. The institution of Dr. Patel has received research support from Astra Zeneca. Dr. Patel has received publishing royalties from a publication relating to health care. Dr. Patel has received personal compensation in the range of $10,000-$49,999 for serving as a Echo Core Lab consultant with Cardiovascular Clinical Sciences.
-
Mr. Ravulapati has nothing to disclose.
-
Author has nothing to disclose